CDK9-IN-27
CAT:
804-HY-155177
Size:
Inquire
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

CDK9-IN-27
- UNSPSC Description: CDK9-IN-27 (Compound 6a) is a CDK9 inhibitor (IC50s: 0.424 μM). CDK9-IN-27 induces apoptosis and cell cycle arrest at S stage. CDK9-IN-27 has cytotoxic action against HepG2, HCT-116 and MCF-7 cell lines, with IC50s of 10.31-40.34 μM. CDK9-IN-27 can be used for cancer research[1].
- Target Antigen: CDK
- Type: Reference compound
- Related Pathways: Cell Cycle/DNA Damage
- Applications: Cancer-Kinase/protease
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/cdk9-in-27.html
- Solubility: 10 mM in DMSO
- Smiles: ClC(C=C1)=CC=C1C(C(C(OCC)=O)=C(N)N2CC3=NC4=CC=CC=C4N3)=C(C#N)C2=O
- Molecular Weight: 447.87
- References & Citations: [1]Husseiny EM, et al. Aminopyridone-linked benzimidazoles: a fragment-based drug design for the development of CDK9 inhibitors. Future Med Chem. 2023 Aug 16.
- Shipping Conditions: Room temperature
- Clinical Information: No Development Reported